Medtronic Loses ICD Market Share, Looks Ahead To U.S. Market Rebound
This article was originally published in The Gray Sheet
Executive Summary
Medtronic is optimistic about a recovery in the implantable cardioverter defibrillator market, despite lower-than-expected sales in its most recent fiscal quarter, reported Feb. 20
You may also be interested in...
Medtronic Preps For Upcoming FDA Panel Meetings On Stent, Spinal Disc
Medtronic is preparing for FDA panel reviews of its Bryan cervical spinal disc in July and itsEndeavor stent this fall, the firm announced May 22
Medtronic Preps For Upcoming FDA Panel Meetings On Stent, Spinal Disc
Medtronic is preparing for FDA panel reviews of its Bryan cervical spinal disc in July and itsEndeavor stent this fall, the firm announced May 22
Boston Scientific’s Improving ICD Sales Offset Slow Stent Revenues In Q1
Boston Scientific's recent resolution of a warning letter pertaining to quality control deficiencies at one of its cardiac rhythm management device manufacturing plants should help increase sales of the implants in the coming quarters, the firm says